BnR Summit 2026

Belt & Road Summit - Deal-Making 2026

9 – 15 Sept 2026 | Hong Kong, China (Hong Kong)

ProjectUpdated on 9 September 2026

Medix ProClot

Regional Director at Medix ProClot

Taiwan

About

Medix ProClot is an agile medical innovator developing next-generation hemostatic (blood-clotting) solutions designed for both human and veterinary applications. By eliminating traditional prescription barriers and addressing regional supply chain inefficiencies, we deliver immediate, high-efficacy wound care across Asia-Pacific and emerging global markets.

Core Innovation & Competitive Edge

Superior Efficacy: Field-tested performance surpassing incumbent trauma gels (e.g., QuikClot, Celox), achieving rapid hemostasis for critical and everyday wound care.

Unlocking the Prescription Gap: Traditional hemostatic agents in APAC often require doctors' prescriptions, creating costly delays for basic bleeding management. We offer direct-access, highly effective solutions that lower barriers for end-users.

Optimized Unit Economics & LTV: Redesigned from cumbersome 30ml bulk units to compact 10ml and 20ml portable formats. This right-sizing accelerates consumption velocity and maximizes Customer Lifetime Value (LTV).

Taiwan Manufacturing Excellence: Partnered with leading Taiwanese CMOs holding extensive US FDA and TFDA clearance track records, ensuring top-tier regulatory compliance and manufacturing quality.

Market Traction & Growth Momentum

Rapid APAC Rollout: Secured MOUs across 4 APAC countries within our first year of operation.

Proven Market Pull: Sustaining strong organic demand without discounting. Recent trade showcases generated 160+ consumer waitlists, along with direct procurement inquiries from national defense units.

Disrupting Legacy Distribution: Traditional distributors of legacy brands face rigid bureaucracy, stock dumping, and a lack of local customer support. We offer direct, agile collaboration backed by genuine localized service—attracting top-tier regional distributors to our network.

Impact-Driven Business Model

Direct-to-Distributor Structure: Eliminates unnecessary middle layers to protect profit margins for all channel partners.

ESG & Social Impact Marketing: Brand awareness driven by direct support to stray animal shelters, capturing high consumer willingness-to-pay through social value.

Subscription & Event Packages: Expanding B2B channels through athletic event emergency kits (e.g., cycling event packages) and recurring membership models.

Project Location

  • United States

Project Website

https://medixproclot.com/videos-2/

Project Format

  • Private Project

Go Global Project

  • Yes

ESG (Environmental, Social, and Governance)

  • Yes

Project Stage

  • Investment / Financing Discussion

Main Project Sector

  • Technology

Technology

  • Bio-Tech
  • Health Technology
  • Medical Technology

Urban Development

  • Health Facilities

Total Project Value

  • 7,500,001 to 10,000,000 USD

Investment Capital Required

  • 2,500,001 to 5,000,000 USD

Interested Format of Cooperation

  • Open for Negotiation

Preferred Financing Model

  • Equity
  • Open for negotiation

Type(s) of Last Financing Round of the project (if Applicable)

  • Equity (private)

Main Service(s) Required

  • Financial Services
  • Professional Services

Financial Services

  • Commercial Banking
  • Investment Banking
  • Mergers & Acquisition
  • Private Banking
  • Private Equity & Venture Capital

Information Technology Services

  • E-commerce

Organisation

Medix ProClot

United States

Similar opportunities